Todeschi, Julien
Dannhoff, Guillaume
Coca, Andres Hugo
Timbolschi, Daniel Ionut
Proust, François
Lefebvre, François
Lelievre, Vincent
Poisbeau, Pierrick
Vallat, Laurent
Salvat, Eric
Bohren, Yohann
Funding for this research was provided by:
PRF process medical company
Article History
Received: 18 January 2023
Accepted: 27 May 2023
First Online: 19 June 2023
Declarations
:
: The study has received approval from the French Research Ethics Committee on 18 January 18 2022 (IRB number 2021-A01985-36). All future changes to the protocol must be verified and validated by the Ethics Committee. These changes will then be communicated to all persons involved in the trial.This trial is registered with ClinicalTrials.gov (NCT05196503). Patients meeting the inclusion criteria will provide written, informed consent form after receiving oral and written information pertaining to the study. Data collected within the trial will be processed in conformity to the Reference Methodology MR001 outlined by the French Data Protection Commission (CNIL).The findings of this study will be disseminated by publication in an international journal and in presentations at international conferences.Participants will be informed of their treatment arm at the end of their participation and will also have access to their gene expression analysis results.
: The authors declare no competing interests.